254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY. - Thieblemont, C.; Row, C.; Lamy, T.; Aucagne, R.; Tani, M.; Merli, M.; Deodato, M.; Usai, S. V.; Minoia, C.; Bommier, C.; Fournier, C.; Bijou, F.; et al. (Hematological oncology, 2025)